CONTACT US   |  (864) 397-5101

Pharma Robots Market are projected to increase at a CAGR of around 13.8% from 2022 – 2032


By 2032, the market for pharmaceutical robots is projected to be worth US$ 683.4 million, growing at a rate of 15.2% annually. The demand for extremely accurate and contaminant-free medications is rising.

-modernization of current pharmaceutical production facilities.
-Worldwide labour shortage, especially in developed economies

Because of the widespread adoption of automation brought about by the fourth industrial revolution, lab automation is now utilised extensively across all industries, including the pharmaceutical industry. Additionally, a significant factor in the growth of the global market for pharmaceutical robots is the requirement for greater precision and accuracy in the manufacturing of pharmaceuticals.

Get a Sample PDF of the Report @

For example, together Clemson University and Nephron Pharmaceuticals Corporation have launched a benchtop robot capable of filling, capping, and sealing sterile pre-filled syringes, saving money by averting drug overfill and reducing adulteration. Without robots, filling syringes remains a highly regulated process that must be carried out by specialized technicians in ISO-certified clean rooms. The robot is intended to assist hospitals and healthcare facilities in dealing with a scarcity of pre-filled syringes. 

Key Takeaways from the Market Study 

  • Global Pharma Robots Market is expected to reach a market size of US$ 188.6 Mn by 2022.  
  • The Traditional Robots segment, is expected to account for the highest CAGR of 14.5% during the forecast period. 
  • United States to remain the most dominant market with an absolute dollar growth opportunity of US$ 153.4 Mn during 2022 – 2032. 
  • The market in Japan is set to experience the highest CAGR of 16.1% during the 2022-2032 forecast period. 

“During the projected period, high dependence on robotics and automation in pharmaceutical companies could boost the demand for Pharma Robots in future.” comments a Future Market Insights analyst.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.